вторник, 25 октября 2016 г.

U.S. FDA approves Merck's lung cancer drug as first-line treatment

U.S. FDA approves Merck's lung cancer drug as first-line treatment


Merck & Co Inc on Monday said the U.S. Food and Drug Administration has approved its immunotherapy Keytruda for use in certain previously untreated lung cancer patients, making it the only approved first-line treatment. The drug has been approved for treating metastatic non-small cell lung cancer patients with high-levels of a protein known for suppressing the immune system called PD-L1.



from Biotech News